Evidence map›Paper›PMID 34906508›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2022

Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma.

Muyi Yang, Per Johnsson, Lars Bräutigam, Xiaohong R Yang, Kim Thrane, Jiwei Gao, Nicholas P Tobin, Yitian Zhou, Rong Yu, Noemi Nagy and 10 more

Open access · greenAbstract read
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Loss of symmetric cell division of apical neural progenitors drivesmedRxiv : the preprint server for health sciences · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 2 countries.

Muyi YangDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Per JohnssonDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden; Ludwig Institute for Cancer Research, Stockholm, Sweden.
Lars BräutigamComparative Medicine, Karolinska Institutet, Stockholm, Sweden.
Xiaohong R YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD.
Kim ThraneDepartment of Gene Technology, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden.
Jiwei GaoDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Nicholas P TobinDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Yitian ZhouSection of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Rong YuDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Noemi NagyDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
Pär G EngströmDepartment of Biochemistry and Biophysics, National Bioinformatics Infrastructure Sweden, SciLifeLab, Stockholm University, Stockholm, Sweden.
Rainer TuominenDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Hanna ErikssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Karolinska University Hospital, Stockholm, Sweden.
Joakim LundebergDepartment of Gene Technology, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden.
Margaret A TuckerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD.
Alisa M GoldsteinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD.
Suzanne Egyhazi-BrageDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Jian ZhaoDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address: jian.zhao@ki.se.
Yihai CaoDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Veronica HöiomDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Karolinska University Hospital, Stockholm, Sweden. Electronic address: veronica.hoiom@ki.se.
Karolinska Institutet · SENational Institutes of Health · USScience for Life Laboratory · SEKarolinska University Hospital · SELudwig Cancer Research · SENational Cancer Institute · USStockholm University · SE

Funding

Family Studies ZIACP004410 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SAVAGE, SHARON A. · 2009 to 2025
$56.1M
Intramural NIH HHS ZIA CP004410
6 · The paper itself

Abstract

purposeMore than half of the familial cutaneous melanomas have unknown genetic predisposition. This study aims at characterizing a novel melanoma susceptibility gene.

methodsWe performed exome and targeted sequencing in melanoma-prone families without any known melanoma susceptibility genes. We analyzed the expression of candidate gene DENND5A in melanoma samples in relation to pigmentation and UV signature. Functional studies were carried out using microscopic approaches and zebrafish model.

resultsWe identified a novel DENND5A truncating variant that segregated with melanoma in a Swedish family and 2 additional rare DENND5A variants, 1 of which segregated with the disease in an American family. We found that DENND5A is significantly enriched in pigmented melanoma tissue. Our functional studies show that loss of DENND5A function leads to decrease in melanin content in vitro and pigmentation defects in vivo. Mechanistically, harboring the truncating variant or being suppressed leads to DENND5A losing its interaction with SNX1 and its ability to transport the SNX1-associated vesicles from melanosomes. Consequently, untethered SNX1-premelanosome protein and redundant tyrosinase are redirected to lysosomal degradation by default, causing decrease in melanin content.

conclusionOur findings provide evidence of a physiological role of DENND5A in the skin context and link its variants to melanoma susceptibility.

Indexed as

MelanomaSkin NeoplasmsAnimalsExome SequencingGenetic Predisposition to DiseaseGuanine Nucleotide Exchange FactorsHumansMelanosomesMonophenol MonooxygenaseSorting NexinsZebrafishDENND5A protein, humanGuanine Nucleotide Exchange FactorsMonophenol MonooxygenaseSNX1 protein, humanSorting NexinsDENND5AMelanomaPigmentationSNX1Susceptibility gene

Identifiers

PMID34906508
PMCPMC10617683
OpenAlexW3216284147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.